Format

Send to

Choose Destination
J Clin Hypertens (Greenwich). 2019 Nov;21(11):1713-1720. doi: 10.1111/jch.13707. Epub 2019 Sep 26.

The effects of topiroxostat on vascular function in patients with hyperuricemia.

Author information

1
Pfizer Japan Inc., Tokyo, Japan.
2
Jichi Medical University School of Medicine, Tochigi, Japan.

Abstract

Xanthine oxidoreductase (XOR) inhibitors, such as allopurinol and febuxostat, inhibit the catalysis of serum uric acid (SUA) synthesis. In doing so, they are thought to improve vascular endothelial function in patients with hyperuricemia and cardiovascular risk by reducing increases in SUA and reactive oxygen species levels. We performed a retrospective cohort study to evaluate the effects of topiroxostat, a novel XOR inhibitor, on vascular function measured by flow-mediated dilation (FMD) on ultrasonography. In total, 23 patients with hyperuricemia were enrolled. After approximately 8 weeks, topiroxostat was associated with a significant increase in the peak percentage change in diameter (∆FMD) from 4.53% ± 2.09% to 5.54% ± 3.08% (P = .045). It also significantly reduced the SUA levels from 7.31 ± 1.43 to 5.44 ± 1.11 mg/dL (P < .001). Although further studies are needed to validate these results, it appears that topiroxostat improves vascular endothelial function in patients with hyperuricemia.

KEYWORDS:

flow-mediated dilation; hyperuricemia; topiroxostat; vascular function; xanthine oxidoreductase

PMID:
31556223
DOI:
10.1111/jch.13707
Free full text

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center